-
1
-
-
0001791734
-
Hedonic prices and implicit markets: product differentiation in pure competition
-
[1] Rosen, S., Hedonic prices and implicit markets: product differentiation in pure competition. J Polit Econ 82 (1974), 34–55.
-
(1974)
J Polit Econ
, vol.82
, pp. 34-55
-
-
Rosen, S.1
-
2
-
-
0004023290
-
Stated Choice Methods: Analytics and Applications
-
Cambridge University Press New York, NY
-
[2] Louviere, J., Hensher, D., Swait, J., Stated Choice Methods: Analytics and Applications. 2000, Cambridge University Press, New York, NY.
-
(2000)
-
-
Louviere, J.1
Hensher, D.2
Swait, J.3
-
3
-
-
3042576511
-
Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics
-
[3] Bridges, J.F., Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2 (2003), 213–224.
-
(2003)
Appl Health Econ Health Policy
, vol.2
, pp. 213-224
-
-
Bridges, J.F.1
-
4
-
-
85009075672
-
The insurance value of medical innovation
-
National Bureau of Economic Research Cambridge, MA
-
[4] Lakdawalla, D., Malani, A., Reif, J., The insurance value of medical innovation. NBER Working Paper No. 21015, 2015, National Bureau of Economic Research, Cambridge, MA.
-
(2015)
NBER Working Paper No. 21015
-
-
Lakdawalla, D.1
Malani, A.2
Reif, J.3
-
5
-
-
84892588228
-
Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
-
[5] Sullivan, S.D., Mauskopf, J.A., Augustovski, F., et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17 (2014), 5–14.
-
(2014)
Value Health
, vol.17
, pp. 5-14
-
-
Sullivan, S.D.1
Mauskopf, J.A.2
Augustovski, F.3
-
6
-
-
0002338136
-
Commercial use of conjoint analysis: a survey
-
[6] Cattin, P., Wittink, D., Commercial use of conjoint analysis: a survey. J Mark 46 (1982), 44–53.
-
(1982)
J Mark
, vol.46
, pp. 44-53
-
-
Cattin, P.1
Wittink, D.2
-
7
-
-
79960121694
-
Discrete choice experiments are not conjoint analysis
-
[7] Louviere, J.J., Flynn, T.N., Carson, R.T., Discrete choice experiments are not conjoint analysis. J Choice Model 3 (2010), 57–72.
-
(2010)
J Choice Model
, vol.3
, pp. 57-72
-
-
Louviere, J.J.1
Flynn, T.N.2
Carson, R.T.3
-
8
-
-
0000142503
-
The choice theory approach to market research
-
[8] McFadden, D., The choice theory approach to market research. Mark Sci 5 (1986), 275–297.
-
(1986)
Mark Sci
, vol.5
, pp. 275-297
-
-
McFadden, D.1
-
9
-
-
0034365737
-
Mixed MNL models for discrete response
-
[9] McFadden, D., Train, K., Mixed MNL models for discrete response. J Appl Econ 15 (2000), 447–470.
-
(2000)
J Appl Econ
, vol.15
, pp. 447-470
-
-
McFadden, D.1
Train, K.2
-
10
-
-
0030796960
-
Using conjoint analysis to assess women's preferences for miscarriage management
-
[10] Ryan, M., Hughes, M., Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ 6 (1997), 261–273.
-
(1997)
Health Econ
, vol.6
, pp. 261-273
-
-
Ryan, M.1
Hughes, M.2
-
11
-
-
0032945923
-
Using conjoint analysis to go beyond health outcomes and take account of patient preferences: an application to in vitro fertilisation
-
[11] Ryan, M., Using conjoint analysis to go beyond health outcomes and take account of patient preferences: an application to in vitro fertilisation. Soc Sci Med 8 (1999), 535–546.
-
(1999)
Soc Sci Med
, vol.8
, pp. 535-546
-
-
Ryan, M.1
-
12
-
-
84872666170
-
A discrete-choice experiment of United Kingdom patients’ willingness to risk adverse events for improved function and pain control in osteoarthritis
-
[12] Hauber, A.B., Arden, N.K., Mohamed, A.F., et al. A discrete-choice experiment of United Kingdom patients’ willingness to risk adverse events for improved function and pain control in osteoarthritis. Osteoarthritis Cartilage 21 (2013), 289–297.
-
(2013)
Osteoarthritis Cartilage
, vol.21
, pp. 289-297
-
-
Hauber, A.B.1
Arden, N.K.2
Mohamed, A.F.3
-
13
-
-
84966698437
-
Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force
-
[13] Hauber, A.B., González, J.M., Groothuis-Oudshoorn, C.G.M., et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health 19 (2016), 300–315.
-
(2016)
Value Health
, vol.19
, pp. 300-315
-
-
Hauber, A.B.1
González, J.M.2
Groothuis-Oudshoorn, C.G.M.3
-
14
-
-
84872731697
-
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
-
[14] Johnson, F.R., Lancsar, E., Marshall, D., et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16 (2013), 3–13.
-
(2013)
Value Health
, vol.16
, pp. 3-13
-
-
Johnson, F.R.1
Lancsar, E.2
Marshall, D.3
-
15
-
-
84903307466
-
Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors
-
[15] Johnson, P., Bancroft, T., Barron, R., et al. Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Value Health 17 (2014), 380–389.
-
(2014)
Value Health
, vol.17
, pp. 380-389
-
-
Johnson, P.1
Bancroft, T.2
Barron, R.3
-
16
-
-
33746298854
-
Using discrete choice experiments within a cost-benefit analysis framework
-
[16] McIntosh, E., Using discrete choice experiments within a cost-benefit analysis framework. Pharmacoeconomics 24 (2006), 855–868.
-
(2006)
Pharmacoeconomics
, vol.24
, pp. 855-868
-
-
McIntosh, E.1
-
17
-
-
1442276463
-
A comparison of stated preference methods for estimating monetary values
-
[17] Ryan, M., A comparison of stated preference methods for estimating monetary values. Health Econ 13 (2004), 291–296.
-
(2004)
Health Econ
, vol.13
, pp. 291-296
-
-
Ryan, M.1
-
18
-
-
84855545457
-
Discrete choice experiments in health economics: a review of the literature
-
[18] De Bekker-Grob, E.W., Ryan, M., Gerard, K., Discrete choice experiments in health economics: a review of the literature. Health Econ 21 (2012), 145–172.
-
(2012)
Health Econ
, vol.21
, pp. 145-172
-
-
De Bekker-Grob, E.W.1
Ryan, M.2
Gerard, K.3
-
19
-
-
84928733114
-
Consistency between stated and revealed preferences: a discrete choice experiment and a behavioural experiment on vaccination behaviour compared
-
[19] Lambooji, M.S., Harmsen, I.A., Veldwijk, J., et al. Consistency between stated and revealed preferences: a discrete choice experiment and a behavioural experiment on vaccination behaviour compared. BMC Med Res Methodol, 15, 2015, 19.
-
(2015)
BMC Med Res Methodol
, vol.15
, pp. 19
-
-
Lambooji, M.S.1
Harmsen, I.A.2
Veldwijk, J.3
-
20
-
-
10344220579
-
Validation of stated preferences for public goods: a comparison of contingent valuation survey response and voting behaviour
-
[20] Schläpfer, F., Roschewitz, A., Hanley, N., Validation of stated preferences for public goods: a comparison of contingent valuation survey response and voting behaviour. Ecol Econ 51 (2004), 1–16.
-
(2004)
Ecol Econ
, vol.51
, pp. 1-16
-
-
Schläpfer, F.1
Roschewitz, A.2
Hanley, N.3
-
21
-
-
84995877260
-
Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses in health and medicine: the Second Panel on Cost-Effectiveness in Health and Medicine
-
[21] Sanders, G.D., Neumann, P.J., Basu, A., et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses in health and medicine: the Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 316 (2016), 1093–1103.
-
(2016)
JAMA
, vol.316
, pp. 1093-1103
-
-
Sanders, G.D.1
Neumann, P.J.2
Basu, A.3
-
22
-
-
0030919507
-
Economic foundations of cost-effectiveness analysis
-
[22] Garber, A.M., Phelps, C.E., Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997), 1–31.
-
(1997)
J Health Econ
, vol.16
, pp. 1-31
-
-
Garber, A.M.1
Phelps, C.E.2
-
23
-
-
0030915977
-
Accounting for future costs in medical cost-effectiveness analysis
-
[23] Meltzer, D., Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16 (1997), 33–64.
-
(1997)
J Health Econ
, vol.16
, pp. 33-64
-
-
Meltzer, D.1
-
24
-
-
51149098773
-
The NICE cost-effectiveness threshold: what it is and what that matters
-
[24] McCabe, C., Claxton, K., Culyer, A.J., The NICE cost-effectiveness threshold: what it is and what that matters. Pharmacoeconomics 26 (2008), 733–744.
-
(2008)
Pharmacoeconomics
, vol.26
, pp. 733-744
-
-
McCabe, C.1
Claxton, K.2
Culyer, A.J.3
-
25
-
-
0033914269
-
Willingness to pay for a quality-adjusted life year: in search of a standard
-
[25] Hirth, R.A., Chernew, M.E., Miller, E., et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20 (2000), 332–342.
-
(2000)
Med Decis Making
, vol.20
, pp. 332-342
-
-
Hirth, R.A.1
Chernew, M.E.2
Miller, E.3
-
26
-
-
41149171625
-
What does the value of modern medicine say about the $50,000 per quality-adjusted life year decision rule?
-
[26] Braithwaite, R.S., Meltzer, D.O., King, J.T., Roberts, M., What does the value of modern medicine say about the $50,000 per quality-adjusted life year decision rule?. Med Care 46 (2008), 349–356.
-
(2008)
Med Care
, vol.46
, pp. 349-356
-
-
Braithwaite, R.S.1
Meltzer, D.O.2
King, J.T.3
Roberts, M.4
-
27
-
-
84923209923
-
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
-
[27] Claxton, K., Martin, S., Soares, M., et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19 (2015), 1–503.
-
(2015)
Health Technol Assess
, vol.19
, pp. 1-503
-
-
Claxton, K.1
Martin, S.2
Soares, M.3
-
28
-
-
84901630147
-
ACC/AHA statement on cost/value methodology in clinical practice guidelines and preference measures
-
[28] Anderson, J.L., Heidenreich, P.A., Barnett, P.A., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and preference measures. J Am Coll Cardiol 63 (2014), 2304–2322.
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 2304-2322
-
-
Anderson, J.L.1
Heidenreich, P.A.2
Barnett, P.A.3
-
29
-
-
84939251874
-
American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options
-
[29] Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33 (2015), 2563–2577.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2563-2577
-
-
Schnipper, L.E.1
Davidson, N.E.2
Wollins, D.S.3
-
30
-
-
84976398620
-
Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received
-
[30] Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
-
(2016)
J Clin Oncol
, vol.34
, pp. 2925-2934
-
-
Schnipper, L.E.1
Davidson, N.E.2
Wollins, D.S.3
-
32
-
-
84952907922
-
Measuring the value of prescription drugs
-
[32] Neumann, P.J., Cohen, J.T., Measuring the value of prescription drugs. N Engl J Med 373 (2015), 2595–2597.
-
(2015)
N Engl J Med
, vol.373
, pp. 2595-2597
-
-
Neumann, P.J.1
Cohen, J.T.2
-
33
-
-
84959574946
-
Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force
-
[33] Marsh, K., IJzerman, M., Thokala, P., et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 19 (2016), 125–137.
-
(2016)
Value Health
, vol.19
, pp. 125-137
-
-
Marsh, K.1
IJzerman, M.2
Thokala, P.3
|